Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.businesswire.com/news/home/20210422005779/en/Asana-BioSciences-to-Present-Additional-Efficacy-Data-from-Chronic-Hand-Eczema-Phase-2b-Trial-of-Oral-SYKJAK-Inhibitor-Gusacitinib-at-AAD-VMX-Late-Breaking-Session
https://www.biospace.com/article/releases/asana-biosciences-to-present-clinical-data-on-oral-asn007-a-novel-erk1-2-inhibitor-at-the-32nd-eortc-nci-aacr-symposium/
https://www.biospace.com/article/releases/asana-biosciences-to-present-positive-results-from-phase-2b-study-of-oral-jak-syk-inhibitor-gusacitinib-in-patients-with-chronic-hand-eczema-in-the-late-breaking-news-session-at-the-eadv-virtual-congress/
https://au.news.yahoo.com/asana-biosciences-announces-positive-topline-120000145.html
https://seekingalpha.com/news/3521948-amedisys-acquires-asana-hospice